MIGENIX to Present Celgosivir Phase II Hepatitis C Results at Digestive Disease Week 2007
MIGENIX to Present Celgosivir Phase II Hepatitis C Results at Digestive Disease Week 2007
About this item
Full title
MIGENIX to Present Celgosivir Phase II Hepatitis C Results at Digestive Disease Week 2007
Publisher
Ottawa: PR Newswire Association LLC
Journal title
Canada NewsWire, 2007, p.1
Language
English
Formats
Publication information
Publisher
Ottawa: PR Newswire Association LLC
Subjects
More information
Scope and Contents
Contents
VANCOUVER and SAN DIEGO, May 18 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases will make a presentation of results from a recent hepatitis C Phase II combination therapy study (see April 11, 2007 press release) in a non-responder patient population at Digestive Disease Week (DDW) 2007 being...
Alternative Titles
Full title
MIGENIX to Present Celgosivir Phase II Hepatitis C Results at Digestive Disease Week 2007
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_wirefeeds_453149848
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_453149848
How to access this item
Log in as a Library member
